<DOC>
	<DOCNO>NCT02984020</DOCNO>
	<brief_summary>The objective study identify problem question respect safety efficacy Xeljanz post-marketing period require regulation MFDS .</brief_summary>
	<brief_title>Korean Post-marketing Surveillance Xeljanz</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>To include study patient receive least 1 dose Xeljanz treatment follow indication per local labelling . Moderately severely active RA adult patient inadequate response intolerance previous therapy least 1 biological DMARD . 1 . Patients history hypersensitivity ingredient product . 2 . Patients serious infection ( eg , sepsis ) active infection include localized infection . 3 . Patients active tuberculosis . 4 . Patients severe hepatic function disorder . 5 . Patients absolute neutrophil count ( ANC ) &lt; 500 cells/mm3 . 6 . Patients lymphocyte count &lt; 500 cells/mm3 . 7 . Patients hemoglobin concentration &lt; 8 g/dL . 8 . Pregnant possibly pregnant woman . 9 . Because lactose contained drug , administer patient hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . According Contraindication label , investigator discontinue patient 's treatment laboratory test result Patients absolute neutrophil count ( ANC ) &lt; 500 cells/mm3 Patients hemoglobin level &lt; 8 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>